New study tests exercise and semaglutide combo to fight cognitive decline in diabetes
NCT ID NCT07485062
First seen Jun 24, 2026 · Last updated Aug 21, 2026 · Updated 3 times
Summary
This study looks at whether supervised exercise and the diabetes drug semaglutide, alone or together, can improve thinking and brain health in older adults with type 2 diabetes. About 164 people aged 65 and older will take part. They will be assigned to exercise training, a control exercise, semaglutide injections, or standard diabetes care for up to 32 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- semaglutide (a diabetes drug) and supervised resistance exercise
- What this could lead to
- If it works, this could point toward a way to protect brain function in older adults with type 2 diabetes using exercise and medication.
- What could go wrong
- This is a phase 4 trial, but it's still early and small. The results may not apply to everyone, and semaglutide can cause side effects like nausea or stomach issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 164 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. 2. Community-dwelling 3. Male or female 4. Age ≥ 65 at the time of signing informed consent 5. Glycated hemoglobin levels of ≥7% (i.e., A1c levels high enough to see intervention-related changes and increase eligibility for recruitment, but can exercise safely) 6. Eligible for the Ontario Drug Benefit (inadequate glycemic control and on max tolerated dose of metformin or metformin contraindicated or inappropriate) 7. Score \>24/30 on the Mini-Mental State Exam (MMSE) 8. Score \>6/8 on the Lawton Instrumental Activities of Daily Living Scale (IADL) 9. Have visual acuity of \>20/40 with or without corrective lenses 10. Speak and understand English fluently 11. Complete the Physical Activity Readiness Questionnaire (PAR-Q+) and obtain physician clearance to start a supervised exercise program 12. Comfortable with a blood draw 13. Not currently engaging in structured resistance exercise more than once per week Exclusion Criteria: 1. Have a medical condition for which semaglutide or exercise is contraindicated 2. Use of a GLP-1 receptor agonist in the past 6 months (i.e., offers removal of Semaglutide from the system as it has a half-life of around 1 week; thus, 8-10 weeks are required for a washout. 3\) Have engaged regularly (\>1/week) in aerobic or RE within the past 6 months 4) Have a neurodegenerative disease (i.e., dementia) or psychiatric condition 5) Have had untreated depression in the past 6 months (6) Have experienced a recent vascular incident (i.e., stroke, myocardial infarction in the last 6 months.) (7) Have severe peripheral neuropathy, an active foot wound, or severe musculoskeletal/joint disease (8) Active or untreated retinopathy (9) Taking psychotropic medications (excluding those for the treatment of depression)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cognitive decline in older adults are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Western University
London, Ontario, N6A 3K7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness and yoga rewire diabetes habits?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Gut microbes in pregnancy and infancy: a window into lifelong health?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Chatbot coach takes aim at diabetes risk after pregnancy